Insider Selling: Personalis (NASDAQ:PSNL) CFO Sells 4,982 Shares of Stock

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 4,982 shares of Personalis stock in a transaction on Monday, June 29th. The shares were sold at an average price of $14.00, for a total transaction of $69,748.00. Following the completion of the sale, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at approximately $2,783,662. This trade represents a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aaron Tachibana also recently made the following trade(s):

• On Friday, June 26th, Aaron Tachibana sold 51,251 shares of Personalis stock. The stock was sold at an average price of $13.18, for a total transaction of $675,488.18.
• On Thursday, June 4th, Aaron Tachibana sold 40,000 shares of Personalis stock. The shares were sold at an average price of $12.01, for a total value of $480,400.00.
• On Friday, May 29th, Aaron Tachibana sold 38,799 shares of Personalis stock. The shares were sold at an average price of $11.58, for a total value of $449,292.42.

Personalis Trading Up 5.6%

PSNL stock traded up $0.73 during trading on Monday, reaching $13.75. 3,772,128 shares of the stock were exchanged, compared to its average volume of 2,086,146. The firm’s 50 day moving average is $8.42 and its 200 day moving average is $8.28. Personalis, Inc. has a twelve month low of $3.84 and a twelve month high of $14.07. The firm has a market cap of $1.44 billion, a P/E ratio of -13.48 and a beta of 2.27.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The firm had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.48 million. As a group, analysts predict that Personalis, Inc. will post -1.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Personalis

A number of institutional investors and hedge funds have recently bought and sold shares of PSNL. T. Rowe Price Investment Management Inc. boosted its holdings in Personalis by 273.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock worth $85,812,000 after acquiring an additional 7,896,714 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Personalis by 1,332.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock valued at $11,531,000 after purchasing an additional 1,347,439 shares in the last quarter. Kennedy Capital Management LLC lifted its position in shares of Personalis by 196.2% during the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after purchasing an additional 1,281,695 shares in the last quarter. Aberdeen Group plc boosted its holdings in Personalis by 36.1% during the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after purchasing an additional 861,948 shares during the last quarter. Finally, ARK Investment Management LLC boosted its holdings in Personalis by 11.3% during the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after purchasing an additional 802,268 shares during the last quarter. 61.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on PSNL. Morgan Stanley reduced their price target on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. BTIG Research decreased their target price on shares of Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Finally, Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Personalis has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.